iBio, Inc. (NYSEAMERICAN:IBIO – Get Rating) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 2,030,000 shares, a drop of 5.6% from the February 13th total of 2,150,000 shares. Based on an average trading volume of 3,220,000 shares, the days-to-cover ratio is currently 0.6 days. Currently, 16.9% of the shares of the stock are sold short.
iBio Stock Performance
Shares of NYSEAMERICAN IBIO opened at $2.03 on Friday. iBio has a 52-week low of $0.36 and a 52-week high of $16.51. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.04.
iBio (NYSEAMERICAN:IBIO – Get Rating) last issued its quarterly earnings data on Tuesday, February 14th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter. iBio had a negative net margin of 2,054.97% and a negative return on equity of 106.69%. On average, equities research analysts anticipate that iBio will post -4.37 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Separately, JMP Securities cut iBio from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 15th.
iBio, Inc is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins.
- Get a free copy of the StockNews.com research report on iBio (IBIO)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.